Securities & Investment Fraud

Prothena Corporation plc Securities Class Litigation

Introduction

Securities fraud class action litigation has been filed on behalf of investors who purchased or otherwise acquired the publicly traded securities of Prothena Corporation plc (“Prothena” or the “Company”) (NYSE: PRTA). If you purchased or otherwise acquired the publicly traded securities of Prothena between October 15, 2015 and April 20, 2018, inclusive (the “Class Period”), you may move the court for appointment as lead plaintiff by no later than July 16, 2018.

You may retain Lieff Cabraser Heimann & Bernstein, LLP, or other attorneys, as your counsel in the actions. Recognized by the National Law Journal as one of the nation’s top plaintiffs’ law firms, Lieff Cabraser is committed to safeguarding the rights of investors and upholding the integrity of the market. We have significant experience and a successful track record of representing institutional and individual investors in securities and financial fraud litigation.

Prothena investors may choose to have Lieff Cabraser review their claim by completing the contact form below. You can also call Sharon M. Lee of Lieff Cabraser at 1-800-541-7358 to discuss the litigation.

Background on the Prothena Securities Class Litigation

Prothena, incorporated in Ireland and with U.S. headquarters in South San Francisco, California, is a development-stage biotechnology company.

The action alleges that Defendants made false and/or misleading statements and/or failed to disclose the results of an ongoing clinical trial for its principal drug, NEOD001, a monoclonal antibody used to treat a rare, debilitating disease that can lead to organ failure and death. According to the Complaint, throughout the Class Period Prothena cited the “best response” results from the Company’s ongoing clinical study of the NEOD001 antibody as evidence that the drug was effective, while withholding relevant trial data showing that the drug was not effective.

Plaintiff alleges that the truth began to emerge through a series of partial disclosures in 2017 and early 2018, culminating with the April 23, 2018 announcement that Prothena was ending all development of NEOD001 after data from the Phase 2b clinical trial showed that NEOD001 failed to reach either its primary or secondary endpoints, and was substantially less effective than the placebo. On this news, the Company’s share price fell 69%, or $25.34, from the previous closing price of $36.84 per share on April 20, 2018 to close at $11.50 per share on April 23, 2018, on extremely elevated trading volume.

Shareholder Contact Form


First Name (required)

Last Name (required)

Email address (required)

Street Address

City

State

Zip

Telephone Day

Telephone Eve

How did you find our site?

Are you currently represented by an attorney?

II. TRANSACTIONS IN PROTHENA SECURITIES

Number of shares of Prothena held immediately before the start of the Class Period on October 15, 2015:

From October 15, 2015 through April 20, 2018, inclusive, I made the following transactions in Prothena securities:

PURCHASES

Date
No. of Shares
Price

show more rows

SALES

Date
No. of Shares
Price

show more rows

During the 90 days after April 20, 2018, I made the following transactions in Prothena securities:

SALES

Date
No. of Shares
Price

show more rows

Comments & questions:

Please sign me up for your Consumer Law newsletter. Yes


About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Seattle, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for 15 years. In compiling the list, the NLJ examines recent verdicts and settlements and looks for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.” Law360 selected Lieff Cabraser as one of the “Top 50 Law Firms Nationwide for Litigation,” highlighting our firm’s “laser focus” and noting that Lieff Cabraser routinely finds itself “facing off against some of the largest and strongest defense law firms in the world.” The publication separately named our firm one of five “2017 California Powerhouses,” the only plaintiffs’ firm on the list. Best Lawyers and U.S. News named Lieff Cabraser as a “Law Firm of the Year” from 2012 through 2016, and the firm has received a number of other recent honors, awards, and recognition, including the National Law Journal’s “Elite Trial Lawyers,” Law360’s “Most Feared Plaintiffs’ Firms,” and Benchmark Litigation’s “Top 10 Plaintiffs Firms in America.”